Alpha Tau Medical Ltd (DRTS) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alpha Tau Medical Ltd., a pioneer in alpha-radiation cancer therapy, has successfully treated its first patient with recurrent lung cancer using its breakthrough Alpha DaRT technology at Hadassah Medical Center in Jerusalem. The clinical trial, which allows for concurrent chemotherapy or immunotherapy, aims to assess the safety, feasibility, and efficacy of Alpha DaRT in treating tumors in the chest area. This development could potentially offer hope to a global patient population with limited treatment options for lung cancer, the leading cause of cancer-related deaths worldwide.
For further insights into DRTS stock, check out TipRanks’ Stock Analysis page.